Ensuring Patient Access to Critical Breakthrough Products Act of 2025

# Ensuring Patient Access to Critical Breakthrough Products Act of 2025 - Summary **What the Bill Would Do:** This bill (S 1717) aims to speed up patient access to new medications and medical treatments that show significant promise in treating serious diseases. The legislation would likely modify FDA approval processes to allow innovative drugs and devices to reach patients more quickly, particularly those designated as "breakthrough" therapies by the FDA because they demonstrate substantial advantages over existing treatments. **Who It Affects:** The bill would impact patients with serious or life-threatening conditions, pharmaceutical and medical device companies developing new treatments, and the FDA's regulatory processes. It could also affect insurance companies and healthcare providers who manage access to these treatments. **Current Status:** The bill was introduced in the 119th Congress by Senator Todd Young (R-IN) and is currently under committee review.

It has not yet been voted on by the full Senate. Without additional details on specific provisions, the exact mechanisms for expediting access remain unclear, but similar legislation typically focuses on streamlining regulatory timelines while maintaining safety standards.